Optimi Health Corp. - Chief Science Officer, Justin Kirkland
Chief Science Officer, Justin Kirkland
Source: Dailyadvent
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Optimi Health Corp.’s (OPTI) subsidiary has been added to a list of approved suppliers to supply psilocybin for medical purposes
  • It is focused on bringing relief to those suffering from mental health trauma
  • The SAP allows medical practitioners to request access to use psilocybin on a case-by-case emergency basis
  •  The company received requests for supply agreements from potential partners
  • Optimi Health Corp.(OPTI) is up 6.67 per cent trading at $0.40 per share as of11:34 a.m. EST

Optimi Health’s (OPTI) subsidiary has been approved under the Special Access Program (SAP) to supply psilocybin for medical purposes.

Optimi is focused on bringing change to those suffering from debilitating palliative and non-palliative mental health trauma.

The SAP allows medical practitioners to request access to use psilocybin on a case-by-case emergency basis.

With Optimi’s license approved by Health Canada earlier this month, it received requests for supply agreements from potential partners interested in the new EU-GMP compliant facility in Princeton, B.C.

Optimi will have a grand opening for its new facility this May and will be building awareness about the benefits of SAP to physicians qualified to recommend the program to patients.

SAP is already displaying a positive impact on patients in need. The program will provide a way for the company to develop and supply the demand for natural psilocybin.

Bill Ciprick, CEO of Optimi, commented

“We will leave no stone unturned in our effort to provide the safest and most efficacious natural psilocybin product in the world, because frankly we need to get this right for those depending on us for support and healing.”

Practitioners were prohibited from requesting access to psilocybin and MDMA for individual psychedelic-assisted psychotherapy until recent amendment changes.

The amendments have the potential to positively affect the lives of people experiencing serious mental health conditions and end-of-life distress when other therapies have failed, are unsuitable or are unavailable in Canada.

Optimi Health Corp.(OPTI) is up 6.67 per cent trading at $0.40 per share as of11:34 a.m. EST.

More From The Market Herald

" Optimi Health (CSE:OPTI) acquires catalog of psychedelic and functional mushroom genetics

Optimi Health (OPTI) has acquired a catalog of psilocybin and functional mushroom strains.

" Nirvana Life Sciences Inc (CSE:NIRV) signs LOI with Innovate Phytotechnologies Inc

Nirvana Life Sciences (NIRV) has  signed a letter of intent with Innovate Phytotechnologies Inc. (INVP)
Clearmind Medicine - CEO, Adi Zuloff Shani.

" Clearmind Medicine (CSE:CMND) announces upcoming pre-IND meeting with the FDA

Clearmind (CMND) will participate in a pre-IND meeting with the FDA on May 18, 2022.
Red Light Holland - Advisor, Akwasi Owusu Bempah.

" Red Light Holland (CSE:TRIP) adds Akwasi Owusu-Bempah to Advisory Board

Red Light Holland (TRIP) has hired drug law expert Akwasi Owusu-Bempah as its newest advisor.